[Relative study of soluble syndecan-1 and prognosis of patients with multiple myeloma].
OBJECTIVE
To investigate the role of soluble syndecan-1 in the pathogenesis of human multiple myeloma (MM).


METHODS
Serum level of soluble syndecan-1 of patients with MM and plasma cell leukemia was determined by ELISA.


RESULTS
(1) The median serum soluble syndecan-1 concentrations of MM patients and controls were 111 ng/ml (41 - 6,300 mg/L) and 63 mg/L (10 - 163 mg/L), respectively (P < 0.005). (2) For 47 myeloma patients, increased serum syndecan-1 concentrations at diagnosis were associated with a poor prognosis. Patients with serum syndecan-1 levels below or above 166 mg/L had significantly different survival times (median > 48 months or < 18 months, respectively, P < 0.0001). (3) Serum soluble syndecan-1 levels were correlated with beta-2 microglobulin concentrations and the percentage of plasma cell.


CONCLUSIONS
Serum levels of circulating soluble syndecan-1 correlated with tumor mass and may exert pleiotropic effects on myeloma cell behavior.
Li
X
X
Institute of Medical Biotechnology, Suzhou University, Suzhou 215007, China.
Zhang
X
X
Lu
Z
Z
Klein
B
B
D006801:Humans; D009101:Multiple Myeloma / Q000097:blood* / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D015996:Survival Rate; D053668:Syndecan-1 / Q000097:blood*; D047368:Tumor Burden
D053668:Syndecan-1